BMC Research Notes (Jul 2018)

Development of a laboratorial platform for diagnosis of schistosomiasis mansoni by PCR-ELISA

  • Carolina Senra,
  • Luciana Inácia Gomes,
  • Liliane Maria Vidal Siqueira,
  • Paulo Marcos Zech Coelho,
  • Ana Rabello,
  • Edward Oliveira

DOI
https://doi.org/10.1186/s13104-018-3571-7
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Objective We developed a laboratorial platform to release a commercial platform used in the PCR-ELISA for the molecular diagnosis of schistosomiasis mansoni. On following, PCR-ELISA platform laboratorial was evaluated in 206 feces samples collected of individual living in a Brazilian low endemicity area. Results The PCR-ELISA laboratorial platform indicated a prevalence rate of 25.2%, which was higher than the Kato-Katz technique (18.4%) and lower than the commercial platform (30.1%). Considering Kato-Katz technique as the reference, there were 97.4% and 91.1% of relative sensitivity and specificity rates, respectively. The laboratorial platform presented good precision, performance diagnostic, and can be used in replacement to the commercial platform for diagnosis of schistosomiasis by PCR-ELISA.

Keywords